RT Journal Article
SR Electronic
T1 Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e000604
DO 10.1136/jitc-2020-000604
VO 8
IS 1
A1 John Haanen
A1 Marc Ernstoff
A1 Yinghong Wang
A1 Alexander Menzies
A1 Igor Puzanov
A1 Petros Grivas
A1 James Larkin
A1 Solange Peters
A1 John Thompson
A1 Michel Obeid
YR 2020
UL http://jitc.bmj.com/content/8/1/e000604.abstract
AB Patients with cancer who developed severe, grade 3 or 4 immune-related adverse events (irAEs) during therapy with immune checkpoint inhibitors are at risk for developing severe toxicities again on rechallenge with checkpoint inhibitors. Consequently, medical oncologists and multidisciplinary teams are hesitant to retreat in this scenario, despite the fact that a number of patients may derive clinical benefit from this approach. Balancing such clinical benefit and treatment-related toxicities for each patient is becoming increasingly challenging as more and more patients with cancer are being treated with checkpoint inhibitors. In this manuscript, we provide an extensive overview of the relevant literature on retreatment after toxicity, and suggest prophylactic approaches to minimize the risk of severe irAE following rechallenge with immune checkpoint blockade, since treatment may be lifesaving in a number of occasions.